How risankizumab moves through the body after IV vs SC dosing in healthy adults
Official title: A Phase 1 Study in Healthy Subjects to Assess Pharmacokinetics Following Intravenous and Subcutaneous Administration of Risankizumab
Run by AbbVie · NCT07466550 · Data updated 2026-11-12
This study tests how risankizumab behaves in the body after intravenous and subcutaneous doses in healthy adult volunteers.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Enrollment | 60 (estimated) |
| Sponsor | AbbVie Industry-sponsored |
| Drugs / interventions | risankizumab |
| Locations | 2 sites (Anaheim, California and 1 other locations) |
| Status | Recruiting |
| Started | June 4, 2026 |
| Main results expected | January 2027 |
| Study ends | January 2027 |
| Registry record updated | July 1, 2026 |
| Trial ID | NCT07466550 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Healthy adults weighing 40–100 kg with BMI 18.0–32.0 kg/m2 and no major health issues or recent interleukin-12/23 treatments.
✕Probably not a fit
People with certain prior immune therapies or those who do not meet the health criteria may not benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This early-phase study compares the pharmacokinetics of risankizumab when given by IV and SC routes in healthy adults. Participants are adults of typical weight who are generally healthy and meet screening criteria. The trial collects data on how the drug is absorbed, distributed, metabolized, and eliminated to understand differences between administration methods. No disease outcomes are being tested, focusing strictly on how the drug moves through the body. The study is sponsored by AbbVie and conducted at sites in Anaheim, CA and Miami, FL.
Why it matters
Potential benefit: Participants may not directly benefit, but results could improve how risankizumab is given in the future.
How similar studies have gone: Other pharmacokinetic studies of risankizumab have provided useful data on IV and SC administration, supporting the feasibility of this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Body weight between 40 kg and 100 kg inclusive at screening and upon initial confinement. * BMI is ≥ 18.0 to ≤ 32.0 kg/m2 after rounding to the tenths decimal at Screening. BMI is calculated as weight in kg divided by the square of height measured in meters. * A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile and a 12-lead ECG. Exclusion Criteria: * Exposure to any anti-interleukin-12/23 or anti interleukin-23 treatment for at least one year prior to Screening. * Intention to perform strenuous exercise to which the subject is unaccustomed within one week prior to administration of first dose of study treatment or during the study.
Where it's running
-
CenExel ACT- Anaheim Clinical Trials /ID# 281821
Anaheim, California, United States Recruiting -
Cpmi /Id# 281783
Miami, Florida, United States Recruiting
Study contacts
- Study coordinator: Abbvie Call Center
- Email: abbvieclinicaltrials@abbvie.com
- Phone: 844-663-3742
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Risankizumab for Refractory Perianal Fistulizing Crohn's Disease
This study tests whether risankizumab can help people with Crohn’s disease who have draining perianal fistulas not responding to other treatments.
-
Guselkumab versus risankizumab for moderate-to-severe Crohn's disease
This comparison tests whether guselkumab or risankizumab works better to reduce intestinal inflammation in people with moderately to severely active Crohn's disease.
-
Comparing five advanced treatments for axial spondyloarthritis and psoriatic arthritis
This project will see how well bimekizumab, risankizumab, guselkumab, upadacitinib, or a TNF inhibitor work for adults with axSpA or PsA who have just started one of these medicines, using medical records and patient surveys.
-
Risankizumab for moderate to severe ulcerative colitis in Japanese adults: change in disease activity
We will see if risankizumab, given as part of routine care, improves disease activity in Japanese adults with moderate to severe ulcerative colitis.
-
Second-line treatment with upadacitinib or risankizumab for adults with Crohn's disease
This project will test how well upadacitinib or risankizumab work as second-line treatments for adults with moderate-to-severe Crohn's disease who previously used a TNF inhibitor.
-
How risankizumab works in children and teens with ulcerative colitis
This trial tests risankizumab in children and adolescents with moderate to severe ulcerative colitis to see how the medicine moves through their bodies and whether it is safe and helps their condition.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.